{"product_id":"bd-swot-analysis","title":"Becton Dickinson SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBecton Dickinson’s robust medical device portfolio and global reach position it strongly amid aging populations and rising healthcare investment, though integration challenges and regulatory scrutiny pose material risks; competitive pressure from medtech innovators and supply-chain volatility temper near-term upside. Discover the full strategic picture with our complete SWOT analysis—purchase the editable, investor-ready report (Word + Excel) for data-driven planning and confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Leadership in Medical Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBD holds a leading share in medical consumables—needles, syringes, collection tubes—fueling about 45% of its 2024 product revenue of $10.1B, giving steady recurring sales because these items are used every patient encounter.\u003c\/p\u003e\n\u003cp\u003eHigh unit volumes yield economies of scale: BD reported manufacturing gross margins of ~38% in FY2024, a cost advantage rivals struggle to match given BD’s global production footprint and procurement scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Revenue Streams Across Three Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBD operates through BD Medical, BD Life Sciences, and BD Interventional, reducing reliance on any single product line and lowering concentration risk.\u003c\/p\u003e\n\u003cp\u003eIn 2025 BD reported revenue of $20.6 billion; each segment contributed meaningfully (BD Medical ~45%, Life Sciences ~30%, Interventional ~25%), which cushions the company against sector-specific downturns.\u003c\/p\u003e\n\u003cp\u003eThis segment mix strengthens cash flow stability and regulatory resilience, helping sustain margins and fund R\u0026amp;D and M\u0026amp;A.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Research and Development Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpby the end of becton dickinson increased r spend to about billion annually prioritizing connected medication management and advanced diagnostics which generated higher margins on new product lines in this sustained investment fuels a pipeline with over active projects targeting unmet clinical needs supporting organic revenue cagr projected through tech edge raises competitor entry costs helped bd expand global market share by percentage points\u003e\n\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Distribution Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBD operates in over 190 countries, giving it one of the largest medtech distribution networks; in FY2024 BD reported revenue of $20.5 billion, with international sales ~48%, enabling fast rollouts and scale in markets from the US to India.\u003c\/p\u003e\n\u003cp\u003eLocal teams ease regulatory approvals and logistics, reducing time-to-market for new products—BD cited over 30 regional regulatory hubs and a global supply chain footprint of 100+ manufacturing and distribution sites in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e190+ countries presence\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue $20.5B; 48% international\u003c\/li\u003e\n\u003cli\u003e100+ manufacturing\/distribution sites\u003c\/li\u003e\n\u003cli\u003e30+ regional regulatory hubs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Reputation and Clinical Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBD’s ~125-year presence in hospitals has built strong clinical trust; FY2024 revenue hit $20.5B, showing durable customer relationships that ease new product adoption.\u003c\/p\u003e\n\u003cp\u003eThat brand equity helps secure multi-year procurement deals—repeat orders lowered churn and supported a 2024 gross margin of ~43%, improving marketing ROI.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e125 years in healthcare\u003c\/li\u003e\n\u003cli\u003e$20.5B revenue FY2024\u003c\/li\u003e\n\u003cli\u003e~43% gross margin FY2024\u003c\/li\u003e\n\u003cli\u003eLower churn, stronger contract wins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD’s global scale fuels $20.6B FY25 revenue, 45% consumables and $1.2B R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBD’s global scale drives recurring sales: FY2025 revenue $20.6B with ~45% from medical consumables; FY2024 gross margin ~38–43% and R\u0026amp;D ~$1.2B (2025). Presence in 190+ countries, 100+ sites, 30+ regulatory hubs, 125-year clinical trust, 40+ active R\u0026amp;D projects; 3.5% organic CAGR to 2027 and 0.9 ppt market share gain in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e$20.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables %\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2025)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal reach\u003c\/td\u003e\n\u003ctd\u003e190+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Becton Dickinson, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to assess the company’s strategic positioning and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix for Becton Dickinson to quickly align strategy and highlight priority risks and opportunities for executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Load from Strategic Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthe aggressive acquisition strategy highlighted by the purchase of edwards lifesciences critical care unit for approximately billion left becton dickinson with elevated leverage net debt rose to about fy2024. servicing interest and principal needs roughly annually reducing free cash flow available r buybacks. analysts flag debt-to-equity ratio near as a key risk that could constrain capital returns internal investment.\u003e\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Regulatory Challenges with Infusion Pumps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing issues and recalls of the Alaris infusion pump system have dented Becton Dickinson’s reputation and led to \u0026gt;$300m in remediation and legal costs through 2023, pressuring margins and contributing to a 2023 operating margin decline of ~220 basis points versus 2021.\u003c\/p\u003e\n\u003cp\u003eDespite extensive fixes and a 2022–2024 compliance program, FDA and EU scrutiny persists, requiring continued CAPAs (corrective and preventive actions) and tying up senior management time.\u003c\/p\u003e\n\u003cp\u003eThese events expose weaknesses in BD’s quality controls for complex electronic devices; product-related recall frequency rose by ~30% in 2021–2023 versus 2018–2020.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Fluctuations in Hospital Capital Budgets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA portion of BD's revenue—about 18% of fiscal 2024 sales ($4.1B of $22.7B total revenue)—comes from large capital-equipment and instrument sales that track hospital capex cycles; when hospitals cut budgets, orders are postponed, contributing to quarterly revenue swings (BD reported 6.5% YoY revenue decline in Q3 FY2024 for its life sciences\/medical segments) and making 12–24 month forecasting less reliable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity and Integration Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBecton Dickinson (BD) faces operational complexity across 60+ manufacturing sites and 50+ acquisitions since 2015, which strained integration — BD reported $16.2B revenue in FY2024 but saw SG\u0026amp;A rise 5% Y\/Y, partly from integration costs.\u003c\/p\u003e\n\u003cp\u003eIntegrating diverse cultures and legacy IT systems caused temporary productivity dips; BD noted restructuring charges of $280M in 2024 tied to consolidation.\u003c\/p\u003e\n\u003cp\u003eSize slows decisions versus smaller rivals; BD’s 2024 operating margin was 13.8%, below some mid-cap peers at ~18%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60+ plants, 50+ acquisitions since 2015\u003c\/li\u003e\n\u003cli\u003e$16.2B revenue FY2024; SG\u0026amp;A +5% Y\/Y\u003c\/li\u003e\n\u003cli\u003e$280M restructuring charges in 2024\u003c\/li\u003e\n\u003cli\u003eOperating margin 13.8% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Specific Raw Material Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBecton Dickinson (BD) relies heavily on plastics, resins and specialty metals for syringes and catheters, so raw-material price swings—oil-linked resin costs up ~18% in 2024—can hit margins if BD cannot pass costs to buyers.\u003c\/p\u003e\n\u003cp\u003eInflation in 2023–24 raised COGS pressure; BD’s 2024 gross margin fell to 39.1%, showing vulnerability without cost pass-through.\u003c\/p\u003e\n\u003cp\u003eBD therefore needs active commodity hedging, multi-sourcing, and long-term contracts to protect profitability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlastics\/resins exposure\u003c\/li\u003e\n\u003cli\u003eOil-linked input volatility ~+18% (2024)\u003c\/li\u003e\n\u003cli\u003eGross margin 39.1% (FY2024)\u003c\/li\u003e\n\u003cli\u003eRequires hedging and multi-sourcing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy debt, recalls dent margins: $16.5B net debt, rising costs squeeze results\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpdebt from the edwards critical care buy raised net debt to pressuring cash for r and buybacks interest annually. recalls cost\u003e$300M through 2023 and drove operating margin down to 13.8% (FY2024); product-quality issues rose ~30% (2021–2023 vs 2018–2020). FY2024 revenue $16.2B; SG\u0026amp;A +5% Y\/Y; gross margin 39.1%; raw-materials up ~18% (2024).\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$16.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEdwards deal (2023)\u003c\/td\u003e\n\u003ctd\u003e$24B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$16.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e13.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e39.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlaris costs through 2023\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct recall rise\u003c\/td\u003e\n\u003ctd\u003e+30% (2021–2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw-materials change (2024)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pdebt\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eBecton Dickinson SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; once purchased, the complete, editable version is unlocked. You’re viewing a live preview of the real file, ready for immediate download after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752345448825,"sku":"bd-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/bd-swot-analysis.png?v=1772239813","url":"https:\/\/matrixbcg.com\/products\/bd-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}